Clinical trial
CP-675,206 Versus Either Dacarbazine Or Temozolomide In Patients Without Prior…
NCT00257205 · AstraZeneca, Industry · Completed
Key facts
| NCT number | NCT00257205 |
|---|---|
| Title | CP-675,206 Versus Either Dacarbazine Or Temozolomide In Patients Without Prior Therapy |
| Official title | A Phase 3, Open Label, Randomized, Comparative Study Of CP-675,206 And Either Dacarbazine Or Temozolomide In Patients With Advanced Melanoma |
| Lead sponsor | AstraZeneca, Industry |
| Status | Completed |
| Phase | Phase 3 |
| Study type | Interventional |
| Conditions | Melanoma |
| Intervention type | Drug |
| Interventions | dacarbazine, CP-675, 206, temozolomide |
| Enrollment | 655 |
| Start date | Mar 1, 2006 |
| Primary completion | Aug 1, 2010 |
| Completion | Aug 1, 2010 |
| First posted | Nov 22, 2005 |
| Last update posted | Jul 2, 2012 |
| Countries | Argentina, Australia, Austria, Belgium, Canada, France, Germany, Greece, Israel, Italy, Mexico, Netherlands and 9 more |
At a glance
- 100–999 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: